City

Chicago (1)

Seattle (1)

Overall Status

Active, not recruiting (1)

Terminated (1)

Phase

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Fred Hutchinson Cancer Center (1)

University of Chicago (1)

Collaborator

National Cancer Institute (NCI) (2)

Intervention

laboratory biomarker analysis (2)

aldesleukin (1)

autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes (1)

cyclophosphamide (1)

pembrolizumab (1)

pharmacogenomic study (1)

therapeutic conventional surgery (1)

Study Documents

Intervention Type

biological (2)

other (2)

drug (1)

procedure (1)

Funder Type

Other (2)

Study Type

Interventional (2)

recurrent pleural malignant mesothelioma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma Trial in Chicago (Pembrolizumab, Laboratory

Active, not recruiting

Biphasic Mesothelioma
+9 more

Pembrolizumab
+2 more

Chicago, Illinois

University of Chicago

Apr 18, 2022

Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma Trial in

Terminated

Has Results

Advanced Pleural Malignant Mesothelioma
+10 more

Aldesleukin
+4 more

Seattle, Washington

Fred Hutch/University of Washington Cancer Consortium

Aug 16, 2021